|
Balance Sheet Cash Flow Statement 10390 Pacific Center Ct. San Diego, CA 92121-4340 CA Tel. 858-646-1100 Fax 858-646-1150 |
Type: Public
On the web:
http://www.vical.com
Employees:
118
Employee growth: (23.4%)
Vical counts DNA as its main ally in the war against infectious disease. The biopharmaceutical firm develops vaccines for the prevention and treatment of viruses and various forms of cancer based on its DNA delivery technology, which uses portions of the genetic code of a pathogen to induce an immune response. Vical has partnered with Merck, Sanofi-Aventis, and National Institutes of Health to fight Hepatitis C, HIV, ebola, and peripheral arterial disease. On its own, it has clinical trials under way for vaccines against Herpes strain cytomegalovirus, flu, and SARS. Its lead product candidate is Allovectin-7, an immunotherapy for melanoma (skin cancer); latter-stage clinical trials are being funded by AnGes MG.
Key numbers for fiscal year ending December, 2008:
Sales: $8.0M
One year growth: 44.3%
Net income: ($36.9)M
Officers:
Chairman: R. Gordon Douglas Jr.
President, CEO, and Director: Vijay B. Samant
SVP Business Operations: Robin M. Jackman
Competitors:
GlaxoSmithKline
Novartis Corporation
Sanofi-Aventis
